Daniel K Nishijima1, John M VanBuren2, Seth W Linakis3, Hilary A Hewes4, Sage R Myers5, Matthew Bobinski6, Nam K Tran7, Simona Ghetti8, P David Adelson9, Ian Roberts10, James F Holmes1, Walton O Schalick11, J Michael Dean2, T Charles Casper2, Nathan Kuppermann12. 1. Department of Emergency Medicine, UC Davis School of Medicine, 4150 V. Street, PSSB 2100, Sacramento, CA, 95817, USA. 2. Department of Pediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA. 3. Department of Pediatrics, Division of Pediatric Emergency Medicine, Ohio State University School of Medicine, Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH, 43205, USA. 4. Department of Pediatrics, Division of Pediatric Emergency Medicine, University of Utah School of Medicine, Primary Children's Hospital, 100 N. Mario Capecchi Dr, Salt Lake City, UT, 84113, USA. 5. Department of Pediatrics, Division of Pediatric Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Children's Hospital of Philadelphia, 3401 Civic Center Blvd. Philadelphia, PA, USA, 19104. 6. Department of Radiology, UC Davis School of Medicine, Stockton Blvd. Sacramento, CA, 95817, USA. 7. Department of Pathology and Laboratory Medicine, University of California, Davis, 4400 V. Street, CA, 95816, USA. 8. Department of Psychology, University of California, Davis, 102K Young Hall, 1 Shields Ave. Davis, CA, 95616, USA. 9. Department of Pediatric Neurosciences, Neurological Institute at Phoenix Children's Hospital, 1919 E. Thomas Rd, Phoenix, AZ, 85016, USA. 10. Clinical Trials Unit, School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK. 11. Department of Orthopedics and Rehabilitation, University of Wisconsin, 317 Knutson Drive, Madison, WI, 53704, USA. 12. Departments of Emergency Medicine and Pediatrics, UC Davis School of Medicine, 4150 V. Street, PSSB 2100, Sacramento, CA, 95817, USA.
Abstract
BACKGROUND: The antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage; however, the drug has not been evaluated in a trial in injured children. We evaluated the feasibility of a large-scale trial evaluating the effects of TXA in children with severe hemorrhagic injuries. METHODS: Severely injured children (0 up to 18th birthday) were randomized into a double-blind randomized trial of 1) TXA 15 mg/kg bolus dose, followed by 2 mg/kg/hr infusion over 8 hours, 2) TXA 30 mg/kg bolus dose, followed by 4 mg/kg/hr infusion over 8 hours, or 3) normal saline placebo bolus and infusion. The trial was conducted at 4 pediatric Level I trauma centers in the United States between June 2018 and March 2020. We enrolled patients under federal exception from informed consent (EFIC) procedures when parents were unable to provide informed consent. Feasibility outcomes included the rate of enrollment, adherence to intervention arms, and ability to measure the primary clinical outcome. Clinical outcomes included global functioning (primary), working memory, total amount of blood products transfused, intracranial hemorrhage progression, and adverse events. The target enrollment rate was at least 1.25 patients per site per month. RESULTS: A total of 31 patients were randomized with a mean age of 10.7 years (standard deviation [SD] 5.0 years) and 22 (71%) patients were male. The mean time from injury to randomization was 2.4 hours (SD 0.6 hours). Sixteen (52%) patients had isolated brain injuries and 15 (48%) patients had isolated torso injuries. The enrollment rate using EFIC was 1.34 patients per site per month. All eligible enrolled patients received study intervention (9 patients TXA 15 mg/kg bolus dose, 10 patients TXA 30 mg/kg bolus dose, and 12 patients placebo) and had the primary outcome measured. No statistically significant differences in any of the clinical outcomes were identified. CONCLUSION: Based on enrollment rate, protocol adherence, and measurement of the primary outcome in this pilot trial, we confirmed the feasibility of conducting a large-scale, randomized trial evaluating the efficacy of TXA in severely injured children with hemorrhagic brain and/or torso injuries using EFIC. This article is protected by copyright. All rights reserved.
BACKGROUND: The antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage; however, the drug has not been evaluated in a trial in injured children. We evaluated the feasibility of a large-scale trial evaluating the effects of TXA in children with severe hemorrhagic injuries. METHODS: Severely injured children (0 up to 18th birthday) were randomized into a double-blind randomized trial of 1) TXA 15 mg/kg bolus dose, followed by 2 mg/kg/hr infusion over 8 hours, 2) TXA 30 mg/kg bolus dose, followed by 4 mg/kg/hr infusion over 8 hours, or 3) normal saline placebo bolus and infusion. The trial was conducted at 4 pediatric Level I trauma centers in the United States between June 2018 and March 2020. We enrolled patients under federal exception from informed consent (EFIC) procedures when parents were unable to provide informed consent. Feasibility outcomes included the rate of enrollment, adherence to intervention arms, and ability to measure the primary clinical outcome. Clinical outcomes included global functioning (primary), working memory, total amount of blood products transfused, intracranial hemorrhage progression, and adverse events. The target enrollment rate was at least 1.25 patients per site per month. RESULTS: A total of 31 patients were randomized with a mean age of 10.7 years (standard deviation [SD] 5.0 years) and 22 (71%) patients were male. The mean time from injury to randomization was 2.4 hours (SD 0.6 hours). Sixteen (52%) patients had isolated brain injuries and 15 (48%) patients had isolated torso injuries. The enrollment rate using EFIC was 1.34 patients per site per month. All eligible enrolled patients received study intervention (9 patients TXA 15 mg/kg bolus dose, 10 patients TXA 30 mg/kg bolus dose, and 12 patients placebo) and had the primary outcome measured. No statistically significant differences in any of the clinical outcomes were identified. CONCLUSION: Based on enrollment rate, protocol adherence, and measurement of the primary outcome in this pilot trial, we confirmed the feasibility of conducting a large-scale, randomized trial evaluating the efficacy of TXA in severely injured children with hemorrhagic brain and/or torso injuries using EFIC. This article is protected by copyright. All rights reserved.
Authors: Lena M Napolitano; Mitchell J Cohen; Bryan A Cotton; Martin A Schreiber; Ernest E Moore Journal: J Trauma Acute Care Surg Date: 2013-06 Impact factor: 3.313
Authors: Ian Roberts; Haleema Shakur; Adefemi Afolabi; Karim Brohi; Tim Coats; Yashbir Dewan; Satoshi Gando; Gordon Guyatt; B J Hunt; Carlos Morales; Pablo Perel; David Prieto-Merino; Tom Woolley Journal: Lancet Date: 2011-03-26 Impact factor: 79.321
Authors: Daniel K Nishijima; Nathan Kuppermann; Ian Roberts; John M VanBuren; Daniel J Tancredi Journal: Ann Emerg Med Date: 2019-01-12 Impact factor: 5.721
Authors: Rachel M Stanley; Michael D Johnson; Cheryl Vance; Lalit Bajaj; Lynn Babcock; Shireen Atabaki; Danny Thomas; Harold K Simon; Daniel M Cohen; Daniel Rubacalva; P David Adelson; Blake Bulloch; Alexander J Rogers; Prashant Mahajan; Jill Baren; Lois Lee; John Hoyle; Kimberly Quayle; T Charles Casper; J Michael Dean; Nathan Kuppermann Journal: Acad Emerg Med Date: 2017-01 Impact factor: 3.451
Authors: Susan E Rowell; Eric N Meier; Barbara McKnight; Delores Kannas; Susanne May; Kellie Sheehan; Eileen M Bulger; Ahamed H Idris; Jim Christenson; Laurie J Morrison; Ralph J Frascone; Patrick L Bosarge; M Riccardo Colella; Jay Johannigman; Bryan A Cotton; Jeannie Callum; Jason McMullan; David J Dries; Brian Tibbs; Neal J Richmond; Myron L Weisfeldt; John M Tallon; John S Garrett; Martin D Zielinski; Tom P Aufderheide; Rajesh R Gandhi; Rob Schlamp; Bryce R H Robinson; Jonathan Jui; Lauren Klein; Sandro Rizoli; Mark Gamber; Michael Fleming; Jun Hwang; Laura E Vincent; Carolyn Williams; Audrey Hendrickson; Robert Simonson; Patricia Klotz; George Sopko; William Witham; Michael Ferrara; Martin A Schreiber Journal: JAMA Date: 2020-09-08 Impact factor: 56.272
Authors: Lehana Thabane; Jinhui Ma; Rong Chu; Ji Cheng; Afisi Ismaila; Lorena P Rios; Reid Robson; Marroon Thabane; Lora Giangregorio; Charles H Goldsmith Journal: BMC Med Res Methodol Date: 2010-01-06 Impact factor: 4.615
Authors: Frank W Moler; Faye S Silverstein; Richard Holubkov; Beth S Slomine; James R Christensen; Vinay M Nadkarni; Kathleen L Meert; Amy E Clark; Brittan Browning; Victoria L Pemberton; Kent Page; Seetha Shankaran; Jamie S Hutchison; Christopher J L Newth; Kimberly S Bennett; John T Berger; Alexis Topjian; Jose A Pineda; Joshua D Koch; Charles L Schleien; Heidi J Dalton; George Ofori-Amanfo; Denise M Goodman; Ericka L Fink; Patrick McQuillen; Jerry J Zimmerman; Neal J Thomas; Elise W van der Jagt; Melissa B Porter; Michael T Meyer; Rick Harrison; Nga Pham; Adam J Schwarz; Jeffrey E Nowak; Jeffrey Alten; Derek S Wheeler; Utpal S Bhalala; Karen Lidsky; Eric Lloyd; Mudit Mathur; Samir Shah; Theodore Wu; Andreas A Theodorou; Ronald C Sanders; J Michael Dean Journal: N Engl J Med Date: 2015-04-25 Impact factor: 91.245